Compare NRP & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NRP | ABCL |
|---|---|---|
| Founded | 2002 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.6B |
| IPO Year | 2002 | 2020 |
| Metric | NRP | ABCL |
|---|---|---|
| Price | $97.60 | $5.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.40 |
| AVG Volume (30 Days) | 36.0K | ★ 6.8M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.56% | N/A |
| EPS Growth | N/A | ★ 10.91 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $216,119,000.00 | $75,128,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $21.85 |
| P/E Ratio | $11.28 | ★ N/A |
| Revenue Growth | 54.66 | ★ 160.56 |
| 52 Week Low | $95.51 | $2.75 |
| 52 Week High | $128.60 | $8.44 |
| Indicator | NRP | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 41.89 | 38.49 |
| Support Level | $97.39 | $5.23 |
| Resistance Level | $101.78 | $5.63 |
| Average True Range (ATR) | 2.26 | 0.54 |
| MACD | 0.20 | -0.25 |
| Stochastic Oscillator | 33.96 | 0.32 |
Natural Resources Partners LP is a diversified natural resource company. It is engaged in the business of owning, managing and leasing a diversified portfolio of mineral properties in the United States, including interests in coal, trona and soda ash, crude oil and natural gas, construction aggregates, frac sand, and other natural resources. The company leases coal reserves to experience mine operators under long-term leases that grant the operator the right to mine its coal reserves in exchange for royalty payments. The company operates in two reportable segments namely: Mineral Rights and Soda Ash. The majority of the revenue is generated from the Mineral Rights segment. Geographically, the company's business activity of the group functions through the United States.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.